News Genmab A/S Nasdaq

Stocks

GMAB

US3723032062

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 06:00:00 01/08/26 am AEST			5-day change	1st Jan Change
28.87 ^USD	+0.80%		-.--%	-6.27%

30/07	Nordic stocks in North America, Ericsson fell 1.7%	FW
24/07	Wall Street's Three-Front Squeeze

All News

Mentions Relevance

24/07	Stocks to Watch : Intel, Deckers, Edwards Lifesciences, Genmab	DJ
24/07	Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)	GL
24/07	Genmab A/S and AbbVie Provide Clarification on Phase 3 EPCORE DLBCL-1 Trial Evaluating Epcoritamab (DuoBody-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma	CI
22/07	TD Cowen Upgrades Genmab to Buy Rating, Boosts PT	MT
22/07	TD Cowen Upgrades Genmab to Buy From Hold, Raises Price Target to $43 From $32	MT
22/07	TD Cowen upgrades Genmab to buy (hold) - BN	FW
21/07	Goldman Sachs raises Genmab price target to 2,350 Danish kroner (2,300), reiterates buy - BN	FW
15/07	Genmab's Darzalex Generates $4.21 Billion in Q2 Net Trade Sales	MT
15/07	Genmab's Darzalex sales totaled $4,207m in the second quarter	FW
15/07	Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026	GL
07/07	Genmab Secures EU Approval for Drug Combination Intended for Relapsed or Refractory Follicular Lymphoma	MT
07/07	Genmab rebounds on a European Commission decision
07/07	EU approves expanded use of Genmab's Tepkinly	FW
07/07	Genmab Wins EU Approval for Follicular Lymphoma Treatment Combination	MT
07/07	Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma	GL
07/07	Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma	BU
07/07	Genmab Announces Tepkinly in Combination with Lenalidomide and Rituximab Is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma	CI
06/07	BNP Paribas raises the target price for Genmab to 2,500 Danish kroner (2,400), reiterates outperform - BN	FW
30/06	Genmab hit a Phase 3 endpoint with epcoritamab in lymphoma	FW
30/06	Genmab Says Epcoritamab Combo Improves Progression-free Survival in Phase 3 Blood Cancer Study	MT
30/06	Genmab Says Epcoritamab Combination Boosts Progression-Free Survival in Phase 3 Lymphoma Trial	MT
30/06	Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival	BU
30/06	Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival	GL
30/06	Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Demonstrating Statistically Significant Improvement in Progression-Free Survival	CI
24/06	AlphaValue/Baader Europe Reduces EPS Estimates for Genmab on Merger Financing Costs	MT